EMA Validates MAA for Tisotumab Vedotin in Recurrent or Meta

The MAA seeking the approval of tisotumab vedotin in select patients with recurrent or metastatic cervical cancer has been validated by the EMA.

Related Keywords

United States , Gonzalez Martin , Pfizer , European Medicines Agency , Fema , Marketing Authorization Application , Maa , Tisotumab Vedotin , Antibody Drug Conjugate , Sadc , Cervical Cancer , Gynecologic Cancer , Phase 3 Innovatv 301 Trial , Phase 2 Innovatv 204 , Genmab ,